文献速递淋巴瘤

种族与社会健康决定因素对接受CAR-T治疗的侵袭性B细胞非霍奇金淋巴瘤患者结局的影响

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.
PubMed 文献 · Blood Adv · 2024-01-01

这项多中心回顾性分析纳入2015至2021年间13个美国学术中心接受CD19 CAR-T治疗的466例复发/难治B细胞非霍奇金淋巴瘤成人患者,中位随访12.7个月。结果显示白种人中位无进展生存期长于非裔美国人或亚裔,且不同保险类型间中位无进展生存期和中位总生存期均存在差异。

要点

  • 不同保险类型间中位无进展生存期和中位总生存期均存在差异(P<.001)。

核心结论

  • 多中心回顾性分析显示,种族和保险状态可影响接受CAR-T治疗患者的结局。

研究设计与样本

  • 多中心回顾性分析,纳入2015至2021年间13个美国学术中心接受CD19 CAR-T治疗的466例复发/难治B细胞非霍奇金淋巴瘤成人患者,中位随访12.7个月。

主要发现

  • 中位总生存期差异无统计学意义。
  • 联邦医疗保险(n=206)vs 医疗补助(n=33)vs 私人保险(n=219)vs 自费(n=7)的中位无进展生存期分别为15.9 vs 4.2 vs 6.0 vs 0.9个月(P<.001)。
  • 联邦医疗保险(n=206)vs 医疗补助(n=33)vs 私人保险(n=219)vs 自费(n=7)的中位总生存期分别为31.2 vs 12.8 vs 21.5 vs 3.2个月(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of the convergence of race and social determinants of health on outcomes for patients treated with CAR-T therapy. We examined the impact of interactions between race and insurance type on health care use and outcomes in patients treated with CAR-T therapy for aggressive B-NHL. Adult patients with r/r B-NHL treated with CD19 CAR-Ts were identified between 2015 and 2021 across 13 US academic centers. Insurance type, demographic, and clinical data were collected and analyzed. In total, 466 adult patients were included in our analysis. Median follow-up after CAR-T therapy was 12.7 months. Median progression-free survival (mPFS) was longer for Caucasians (11.5 months) than for African Americans (3.5 months; hazard ratio [HR], 1.56 [1.03-2.4]; P = .04) or Asians (2.7 months; HR, 1.7 [1.02-2.67]; P = .04). Differences in median overall survival (mOS) were not significant. For Medicare (n = 206) vs Medicaid (n = 33) vs private insurance (n = 219) vs self-pay (n = 7): mPFS was 15.9 vs 4.2 vs 6.0 vs 0.9 months (P < .001), respectively; and mOS was 31.2 vs 12.8 vs 21.5 vs 3.2 months (P < .001), respectively. Our multicenter retrospective analysis showed that race and insurance status can affect outcomes for patients treated with CAR-T therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Karmali R, Machhi R, Epperla N, et al. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024. PMID: 38531057. doi:10.1182/bloodadvances.2023011996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。